Certara, Inc. (CERT) has a MoatMap StockRank of 40/100 based on Quality (48/100), Value (54/100), and Momentum (25/100) factor scores. The current signal is HOLD. Certara is the global leader in biosimulation software, which helps biopharma companies optimize drug development and reduce clinical trial costs. It is an asset-light business with high switching costs, but near-term biotech funding constraints have temporarily slowed its growth trajectory.
Certara, Inc. is a global leader in biosimulation software and technology-enabled services, which are critical for optimizing drug discovery, development, and regulatory submissions for pharmaceutical and biotech companies. Its competitive advantage lies in its proprietary, industry-standard modeling and simulation platform, coupled with deep scientific expertise that accelerates R&D and reduces clinical trial costs.
| Price | $5.18 |
| Market Cap | $882M |
| P/E (Forward) | 13.57 |
| Price/Book | 0.85 |
| Return on Equity | -1.4% |
| Return on Invested Capital | 1.9% |
| Debt/Equity | 29.95 |
| Gross Margin | 61.6% |
| Operating Margin | 3.8% |
| Revenue Growth | 0.9% |
| Free Cash Flow | $117M |
Certara, Inc. operates in the Health Information Services industry, part of the Healthcare sector (United States).